Keywords: Amylin, Second-quarter 2011 financial results, Byetta, Bydureon

Amylin posts smaller 2nd-qtr 2011 loss despite lower Byetta sales

Article | 27 July 2011

Print This

US biotech Amylin Pharmaceuticals (Nasdaq: AMLN) saw its shares all 4.9% to $12.65 after it reported financial results for the quarter ended ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in